A Semaine Health evidence guide comparing the most common non-antibiotic urinary-support options by mechanism and clinical evidence, updated to the latest high-quality trials. Sources linked throughout.
The short answer
The non-antibiotic options for urinary tract health work through different mechanisms and have very different quality of evidence, and the picture has shifted as larger trials have read out. Cranberry's active compounds (PACs) reduce E. coli adhesion to the urinary tract lining, and the largest, highest-quality review to date now finds a real preventive effect, including in women with recurrent UTIs. The catch is delivery form (juice vs standard extract vs phytosome): PACs only help if they are actually absorbed. D-mannose works by a separate mechanism (blocking the E. coli FimH "grip" protein), and early small trials looked promising, but the largest and best-designed trial since then found no benefit over placebo. Two clinician-directed options round out the picture: methenamine hippurate (a urinary antiseptic) and, for postmenopausal women, vaginal estrogen. Here is how they compare.
How each option works (mechanism)
| Option | How it's proposed to work | What's actually measured |
|---|---|---|
| Cranberry juice | PACs reduce E. coli adhesion | PACs poorly absorbed from juice; inconsistent clinical results (Howell 2010) |
| Standard cranberry extract/pills | Higher PAC dose, same anti-adhesion idea | Dose-dependent anti-adhesion if enough PAC is absorbed; results vary with dose/form (Howell 2010; Babar 2021, null primary endpoint) |
| Cranberry phytosome (e.g. Anthocran®) | Phospholipid delivery so PACs survive digestion and reach urine | Compounds measured arriving in human urine; clinical signal in an RCT (Baron 2019; Rondanelli 2024) |
| D-mannose | Sugar that masks the E. coli FimH adhesin so it can't grip the bladder wall | FimH-masking mechanism confirmed in the lab (Scribano 2020); the largest RCT to date found no clinical benefit over placebo (Hayward 2024, MERIT) |
| Methenamine hippurate | Converts to formaldehyde in acidic urine, a non-antibiotic urinary antiseptic | In an RCT, non-inferior to daily preventive antibiotics for recurrent UTI (Harding 2022, ALTAR) |
| Vaginal estrogen (postmenopausal) | Restores estrogen locally to the urogenital tissue and microbial environment | Reduces recurrent UTIs in postmenopausal women; a clinician-directed, guideline-supported option (Buck & Rubin 2020) |
What the clinical evidence shows
Cranberry (overall): the evidence has strengthened. The most comprehensive review to date, a 2023 Cochrane meta-analysis of 50 studies (n=8,857), found cranberry products reduced the risk of UTIs by about 30% overall (RR 0.70, 95% CI 0.58–0.84), and by about 26% in women with recurrent UTIs specifically (RR 0.74, 95% CI 0.55–0.99) (Williams et al., 2023, Cochrane Database Syst Rev). That builds on an earlier meta-analysis of 7 RCTs (n=1,498) that found a 26% reduction in healthy women (Fu et al., 2017, J Nutr). Results still vary across products: a 2016 JAMA trial in nursing-home women found no benefit (Juthani-Mehta et al., 2016), and a 2021 high-dose PAC trial missed its primary endpoint (Babar et al., 2021). The through-line: dose and delivery explain much of the disagreement.
Cranberry phytosome (specifically). When the absorption problem is solved, the picture sharpens. The phytosome's compounds have been measured arriving in human urine and acting there (Baron et al., 2019), and a 2024 double-blind RCT found 120 mg/day of standardized cranberry phytosome significantly modulated urinary tract episodes vs placebo in diabetic postmenopausal women on SGLT-2 inhibitors, a high-risk group (Rondanelli et al., 2024, Nutrients).
D-mannose: the evidence has weakened. Early, small trials were promising: a 2020 meta-analysis reported a large reduction in recurrence vs placebo (pooled RR 0.23) (Lenger et al., 2020, Am J Obstet Gynecol). But that early signal has since been superseded. The largest and highest-quality randomized trial to date, the MERIT trial (598 women with recurrent UTI), found no benefit of D-mannose over placebo (51.0% vs 55.7% with a further UTI, not significant) and concluded that D-mannose should not be recommended for prophylaxis (Hayward et al., 2024, JAMA Intern Med). A 2025 meta-analysis pooling that trial with three earlier ones (890 women total) reached the same bottom line: no statistically significant reduction in recurrent UTI risk (RR 0.44, 95% CI 0.18–1.11), though the authors note substantial heterogeneity across the pooled trials and call for more placebo-controlled RCTs before drawing firm conclusions (Murali Krishna et al., 2025, J Infect Prev). The FimH-masking mechanism is real in the lab (Scribano 2020), but mechanism has not translated into a confirmed preventive benefit across the trials run so far.
Methenamine hippurate. For women who want a non-antibiotic prescription option, the ALTAR trial found methenamine hippurate non-inferior to daily preventive antibiotics for recurrent UTI, making it a legitimate antibiotic-sparing choice to discuss with a clinician (Harding et al., 2022, ALTAR).
Vaginal estrogen (postmenopausal women). Because declining estrogen is the root driver of rising UTI risk after menopause, restoring it locally is one of the better-supported preventive options for this group. Vaginal estrogen reduces recurrent UTIs in postmenopausal women and is endorsed in urology guidance (Buck & Rubin, 2020, Urology). It is a prescription option: discuss it with your clinician. (For why this happens at menopause, see our menopause and urinary health guide.)
Side-by-side summary
| Cranberry phytosome | Standard cranberry | Vaginal estrogen | Methenamine | D-mannose | |
|---|---|---|---|---|---|
| Primary mechanism | Anti-adhesion, delivered | Anti-adhesion | Restores urogenital estrogen | Urinary antiseptic | FimH masking |
| Absorption of actives | Enhanced (phospholipid) | Variable | N/A (local) | N/A | N/A (sugar) |
| Evidence quality | RCT + mechanism in right form | Positive overall; dose-dependent | Strong in postmenopausal women | Non-inferior to antibiotics (RCT) | Largest RCT found no benefit |
| Who it's for | Daily preventive support | Daily, dose matters | Postmenopausal, clinician-directed | Recurrent UTI, clinician-directed | No longer recommended for prevention |
How to read this if you're choosing
- If cranberry "didn't work" for you before, the likely culprit is form and absorption, not cranberry itself. A standardized, bioavailability-enhanced form is the version with both the mechanism-to-urine evidence and the strongest overall clinical review behind it (Williams 2023).
- D-mannose has moved down the list. The early enthusiasm came from small trials; the largest, best-designed trial found no benefit over placebo and advised against using it for prevention (Hayward 2024).
- Methenamine hippurate is a non-antibiotic prescription option that held its own against daily antibiotics in a trial, worth raising with a clinician if recurrence is the problem (Harding 2022).
- For postmenopausal women, vaginal estrogen addresses the root cause and has strong preventive evidence. It's a clinician-directed option: discuss it at your next visit (Buck & Rubin 2020).
- None of the over-the-counter options treat an active infection. They are daily, preventive support for a healthy urinary environment. See a clinician for symptoms of an active UTI.
How Semaine approaches this
Semaine's Urinary Tract Cleanse & Protect is built on Anthocran® Phytosome®, the specific cranberry phytosome used in the published research above, paired with standardized hibiscus to support the urinary environment. It's the "delivery-form-that-actually-absorbs" approach, taken daily.
Curious how this stacks up against a specific competitor product? See our ingredient-by-ingredient comparison with Uqora.
Frequently asked questions
Is cranberry or D-mannose better for UTIs?
The evidence now favors cranberry. The largest review to date found cranberry reduced UTI risk overall and in women with recurrent UTIs (Williams 2023), while the largest trial of D-mannose found no benefit over placebo and concluded it should not be recommended for prevention (Hayward 2024).
Why is cranberry juice considered ineffective?
The active PACs are poorly absorbed from juice, so they don't reach the urinary tract at a meaningful dose (Howell et al., 2010).
What makes cranberry phytosome different from regular cranberry pills?
Phytosome delivery binds the compounds to phospholipids so more survives digestion; the compounds have been measured in human urine after dosing, and a standardized phytosome showed clinical benefit in an RCT (Baron 2019; Rondanelli 2024).
Does D-mannose work for recurrent UTIs?
Early small trials were promising, but the largest and highest-quality randomized trial (598 women) found no benefit over placebo (51.0% vs 55.7% had a further UTI) and concluded D-mannose should not be recommended for prevention (Hayward et al., 2024, MERIT). A 2025 meta-analysis pooling that trial with three earlier ones (890 women total) reached the same conclusion: no statistically significant benefit (RR 0.44, 95% CI 0.18–1.11) (Murali Krishna et al., 2025). The earlier favorable meta-analysis (Lenger 2020) has been superseded by both.
What are the non-antibiotic options for recurrent UTIs?
Beyond standardized cranberry, two clinician-directed options have good evidence: methenamine hippurate was non-inferior to daily preventive antibiotics in a trial (Harding 2022), and for postmenopausal women, vaginal estrogen reduces recurrence (Buck & Rubin 2020). Discuss both with your clinician.
Educational content; not medical advice. Sources peer-reviewed and indexed on PubMed.
References
- High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol. 2021. DOI: 10.1186/s12894-021-00811-w · PubMed
- Profiling metabolites and behavioral effects in urine of humans after cranberry ingestion. Biochem Pharmacol. 2019. DOI: 10.1016/j.bcp.2019.113726 · PubMed
- D-mannose for the prevention of recurrent urinary tract infection. Urology. 2020. DOI: 10.1016/j.urology.2020.05.058
- Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr. 2017. DOI: 10.3945/jn.117.254961 · PubMed
- Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women (ATAFUTI): a multicentre, randomised, open-label trial. NIHR Journals Library (HTA). 2022. DOI: 10.3310/QOIZ6538
- D-mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Intern Med. 2024. DOI: 10.1001/jamainternmed.2024.0264 · PubMed
- Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010. DOI: 10.1186/1471-2334-10-94 · PubMed
- Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes: A Randomized Clinical Trial. JAMA. 2016. DOI: 10.1001/jama.2016.16141 · PubMed
- D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020. DOI: 10.1016/j.ajog.2020.05.048 · PubMed
- D-Mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis of randomized controlled trials. J Infect Prev. 2025. DOI: 10.1177/17571774251394869
- Highly Standardized Cranberry Extract Phytosome (Anthocran®) Modulated the Number of UTI Episodes in Diabetic Postmenopausal Women Undergoing SGLT-2 Inhibitor Treatment. Nutrients. 2024. DOI: 10.3390/nu16132113 · PubMed
- d-Mannose Treatment neither Affects Uropathogenic Escherichia coli Viability nor Biofilm Formation. Molecules. 2020. DOI: 10.3390/molecules25020316 · PubMed
- Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023. DOI: 10.1002/14651858.CD001321.pub6 · PubMed
